혈관 스텐트 시장 예측(-2029년) : 기술별, 제품별, 딜리버리 모드별, 재료별, 최종사용자별, 지역별

The global vascular stent market is projected to reach USD 15.6 billion by 2029 from USD 11.4 billion in 2024, at a CAGR of 6.5% from 2024 to 2029. The growth of the market is driven by increase in acquisitions by major players, increase in adoption of minimally invasive procedures. However, availability of alternative treatment methods to treat vascular disease, is impacting the growth of the market. Moreover, the product recalls and failures in the field of vascular stent are a major factor restraining the market growth.

"Polymer segment to witness the significant growth during the forecast period."

Based on material, the segment is divided into metallic material, and polymer material. The polymer segment is further divided into biodegradable polymers and non-biodegradable polymers. In 2023, among these two polymers, the biodegradable polymer segment to witness the highest growth in vascular stent market. Because of their prospective medicinal uses, biodegradable polymers are expected to witness significant expansion in the vascular stent market. These polymers, which are essential for drug-eluting stent (DES) platforms, guarantee the antiproliferative medications' optimum release, leading to the best possible DES performance. Compared to permanent polymers, biodegradable polymers can reduce chronic inflammation of the arterial wall, hence reducing the risk of late restenosis and stent thrombosis. Clinical experiments have demonstrated that biodegradable polymer DES platforms function similarly to permanent polymer DES platforms during the first year of implantation, with longer-term follow-ups revealing encouragingly lower rates of stent thrombosis. The promise to increase patient safety and efficacy is what motivates their planned market expansion.

"Peripheral segment accounted for the significant growth in the vascular stent market during the forecast period."

Based on product, the vascular stent market is segmented into coronary stents, peripheral stents, and EVAR stent grafts. Among these in 2023, peripheral stents accounted for significant share. Throughout the projected period, peripheral stents are anticipated to have substantial growth in the vascular stent market, driven by the increased prevalence of peripheral vascular illnesses, especially in the aging population. The American Heart Association revealed in June 2023 that 200 million people worldwide and approximately 12 million Americans suffer with peripheral vascular disease (PAD). This rising prevalence highlights the need for efficient treatment alternatives such as Stents for the periphery. Additionally, developments in biodegradable polymer stents provide a more patient-centered, minimally invasive approachable substitute, increasing their uptake and market expansion even more.

"APAC is estimated to register the highest CAGR during the forecast period."

In this report, the vascular stent market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. During the forecast period, the Asia Pacific region is anticipated to experience the largest growth in the vascular stent market by material, mainly because of the increasingly aging population that is causing an increase in the frequency of cardiovascular illnesses. As of June 2022, the population of Asia and the Pacific is aging at a rate faster than any other region in the world, with 630 million people in the region making up 60% of the world's senior population, according to the Economic and Social Commission for Asia and the Pacific. By 2050, it is anticipated that this number would increase to 1.3 billion, greatly increasing the need for vascular stents to treat age-related cardiovascular diseases and propelling market expansion.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW (16%)

List of Companies Profiled in the Report

• Medtronic Plc (Ireland)
• Abbott Laboratories (US)
• Boston Scientific Corporation (US)
• B Braun SE (Germany)
• Terumo Corporation (Japan)
• Biotronik SE & Co.KG (Germany)
• Shanghai Microport Medical (Group) Co., Ltd (China)
• Meril Life Science Pvt. Ltd (India)
• Sahajanan Medical Technologies Limited (India)
• Becton, Dickinson, and Company (US)
• W.L. Gore & Associates, Inc (US)
• Cordis Corporation (US)
• Artivion Inc (US)
• Stryker Corporation (US)
• LifeTech Scientific Corporation (China)
• Translumina (Germany)
• Lepu Medical Technology (Beijing) Co., Ltd (China)
• Endologix LLC. (US)
• Biosensors International Group, Ltd (Singapore)
• Cook Medical (US)
• Insitu Technologies Inc (US)
• iVascular (Spain)
• OrbusNeich Medical Group Holdings Limited (China)
• Alvimedica (Turkey).
• Elixir Medical (US)

Research Coverage

This report studies the vascular stent market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total vascular stent market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (rising incidence of vascular diseases and growth in number of angioplasty procedures, advancements in stent technology and materials, increase in adoption of minimally invasive procedures),restraints (Availability of alternative treatment methods for vascular diseases, stringent regulations for product approval, product failures and recalls), challenges (High risk of complications, declining cost of stent), opportunities (Development of bioresorbable vascular scaffold stent, emerging markets to offer high-growth opportunities for market participants, increase in aging population) contributing the growth of the vascular stent market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the vascular stent market.
• Market Development: Comprehensive information on the lucrative emerging markets, technology, product, mode of delivery, material, end-user and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the vascular stent market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global vascular stent market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET RANKING ANALYSIS
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 VASCULAR STENTS MARKET OVERVIEW
• 4.2 NORTH AMERICA: VASCULAR STENTS MARKET, BY PRODUCT
• 4.3 GEOGRAPHIC SNAPSHOT OF VASCULAR STENTS MARKET
• 4.4 VASCULAR STENTS MARKET: REGIONAL MIX, 2024-2029 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of vascular diseases and subsequent rise in angioplasty procedures
    • 5.2.1.2 Technological advancements in stents
    • 5.2.1.3 Growing preference for minimally invasive surgeries
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Availability of open surgical procedures to hinder market growth
    • 5.2.2.2 Stringent regulatory guidelines for product approval
    • 5.2.2.3 Product failures and recalls
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Development of bioresorbable vascular scaffold stents
    • 5.2.3.2 High growth potential of emerging markets
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complications associated with stenting procedures
    • 5.2.4.2 Declining cost of stents
• 5.3 INDUSTRY TRENDS
  • 5.3.1 COMBINATION THERAPIES
  • 5.3.2 PERSONALIZED MEDICINE
  • 5.3.3 EXPANDING APPLICATIONS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 3D printing
    • 5.4.1.2 Electrospinning
    • 5.4.1.3 Balloon-expandable stents
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Element simulation technology
    • 5.4.2.2 Stereolithography (SLA) technology
    • 5.4.2.3 Laser-cutting technology
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Continuous sinusoid technology
    • 5.4.3.2 Micro-injection molding technology
    • 5.4.3.3 Imaging technology
• 5.5 PORTER'S FIVE FORCE ANALYSIS
  • 5.5.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.5.2 BARGAINING POWER OF SUPPLIERS
  • 5.5.3 BARGAINING POWER OF BUYERS
  • 5.5.4 THREAT OF SUBSTITUTES
  • 5.5.5 THREAT OF NEW ENTRANTS
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
    • 5.6.1.1 North America
      • 5.6.1.1.1 US
      • 5.6.1.1.2 Canada
    • 5.6.1.2 Europe
    • 5.6.1.3 Asia Pacific
      • 5.6.1.3.1 Japan
      • 5.6.1.3.2 China
    • 5.6.1.4 Latin America
    • 5.6.1.5 Middle East & Africa
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS IN VASCULAR STENTS MARKET
  • 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 TRADE ANALYSIS FOR VASCULAR STENTS
• 5.9 PRICING ANALYSIS
• 5.10 KEY CONFERENCES & EVENTS
• 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 BUYING CRITERIA
• 5.12 UNMET NEEDS
• 5.13 END-USER EXPECTATIONS
• 5.14 IMPACT OF GENERATIVE AI ON VASCULAR STENTS MARKET
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: UTILIZATION OF GORE VIABAHN VBX BALLOON-EXPANDABLE STENTS FOR ANGIOGRAPHY PROCEDURE
  • 5.16.2 CASE STUDY 2: SUCCESSFUL TREATMENT OF PATIENT WITH SEVERE CAROTID ARTERY STENOSIS
  • 5.16.3 CASE STUDY 3: W.L. GORE UTILIZED VBX BALLOON-EXPANDABLE STENT FOR ILIAC ARTERY STENOSIS TREATMENT
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.19 INVESTMENT & FUNDING SCENARIO
• 5.20 ADJACENT MARKET ANALYSIS
  • 5.20.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET

6 VASCULAR STENT MARKET, BY TECHNOLOGY

• 6.1 INTRODUCTION
• 6.2 DRUG-ELUTING STENTS
  • 6.2.1 LONG-TERM BENEFITS ASSOCIATED WITH DRUG-ELUTING STENTS TO DRIVE MARKET
• 6.3 BARE METAL STENTS
  • 6.3.1 COST-EFFICIENT BENEFITS TO FUEL UPTAKE
• 6.4 COVERED STENTS
  • 6.4.1 UTILIZATION IN ENDOVASCULAR REPAIR AND VASCULAR LESIONS TO DRIVE MARKET
• 6.5 BIOABSORBABLE STENTS
  • 6.5.1 ABILITY TO MINIMIZE COMPLICATIONS ASSOCIATED WITH PERMANENT DEVICES TO SUPPORT MARKET GROWTH

7 VASCULAR STENTS MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 CORONARY STENTS
  • 7.2.1 INCREASING PREVALENCE OF CORONARY ARTERY DISEASE TO PROPEL MARKET
• 7.3 PERIPHERAL STENTS
  • 7.3.1 CAROTID ARTERY STENTS
    • 7.3.1.1 Rapid recovery time and lower risk of myocardial ischemia to boost demand
  • 7.3.2 FEMORAL ARTERY STENTS
    • 7.3.2.1 Minimal incisions and shorter recovery time to fuel market
  • 7.3.3 RENAL ARTERY STENTS
    • 7.3.3.1 Rising incidence of hypertension and FMD to support market growth
  • 7.3.4 ILIAC ARTERY STENTS
    • 7.3.4.1 Increasing prevalence of atherosclerosis to fuel uptake
  • 7.3.5 OTHER PERIPHERAL STENTS
• 7.4 EVAR STENT GRAFTS
  • 7.4.1 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS
    • 7.4.1.1 Rising incidence of AAA cases to drive market
  • 7.4.2 THORACIC AORTIC ANEURYSM STENT GRAFTS
    • 7.4.2.1 Rising prevalence of renal artery stenosis to support market growth

8 VASCULAR STENTS MARKET, BY MODE OF DELIVERY

• 8.1 INTRODUCTION
• 8.2 BALLOON-EXPANDABLE STENTS
  • 8.2.1 ABILITY TO TREAT CORONARY VESSEL DAMAGE TO DRIVE MARKET
• 8.3 SELF-EXPANDING STENTS
  • 8.3.1 HIGH UPTAKE IN ABDOMINAL & THORACIC EVAR PROCEDURES TO PROPEL MARKET

9 VASCULAR STENTS MARKET, BY MATERIAL

• 9.1 INTRODUCTION
• 9.2 METALLIC MATERIALS
  • 9.2.1 COBALT CHROMIUM
    • 9.2.1.1 Biocompatibility properties to boost demand
  • 9.2.2 PLATINUM CHROMIUM
    • 9.2.2.1 Enhanced visibility and superior radial strength to support market growth
  • 9.2.3 NICKEL TITANIUM
    • 9.2.3.1 Growing adoption of MIS procedures to boost demand
  • 9.2.4 STAINLESS STEEL
    • 9.2.4.1 High reliability and cost-efficiency to boost uptake
• 9.3 POLYMERIC MATERIALS
  • 9.3.1 BIODEGRADABLE POLYMERS
    • 9.3.1.1 Advantages offered by biodegradable polymers to drive market
  • 9.3.2 NON-BIODEGRADABLE POLYMERS
    • 9.3.2.1 Inert alternative to potential inflammatory responses to support market growth

10 VASCULAR STENTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 RISING NUMBER OF ANGIOPLASTY PROCEDURES TO FUEL MARKET
• 10.3 CARDIAC CENTERS
  • 10.3.1 INCREASING CASES OF STROKE TO DRIVE MARKET

11 VASCULAR STENTS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 Supportive regulatory policies for cardiovascular product commercialization to fuel uptake
  • 11.2.3 CANADA
    • 11.2.3.1 Rising incidence of peripheral artery disease to drive market
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising uptake of angioplasty procedures to fuel market
  • 11.3.3 UK
    • 11.3.3.1 Increasing incidence of acute coronary syndrome to propel market
  • 11.3.4 FRANCE
    • 11.3.4.1 Rising incidence of chronic diseases to drive market
  • 11.3.5 ITALY
    • 11.3.5.1 Rising cases of atherosclerotic CVD to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Increasing prevalence of obesity to boost demand
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Growing demand for peripheral artery stents to drive market
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing preference for PCI surgeries to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Improvements in healthcare policies for affordable medical devices to propel market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rising hospitalization rates due to CAD cases to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising incidence of diabetes to boost demand
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growing demand for advanced medical equipment to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Increasing imports of medical devices to fuel market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Increasing prevalence of hypertension to drive market
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VASCULAR STENTS MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
  • 12.4.1 RANKING OF KEY MARKET PLAYERS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Technology footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Mode of delivery footprint
    • 12.5.5.5 Material footprint
    • 12.5.5.6 End-user footprint
    • 12.5.5.7 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 MEDTRONIC PLC
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ABBOTT LABORATORIES
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 BOSTON SCIENTIFIC CORPORATION
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 B. BRAUN SE
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Key strengths
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses & competitive threats
  • 13.1.5 TERUMO CORPORATION
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 BIOTRONIK SE & CO. KG.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
  • 13.1.7 SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
  • 13.1.8 MERIL LIFE SCIENCES PVT. LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 BECTON, DICKINSON AND COMPANY
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 W. L. GORE & ASSOCIATES, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches & approvals
  • 13.1.12 CORDIS CORPORATION (SUBSIDIARY OF HELLMAN & FRIEDMAN LLC)
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product approvals
      • 13.1.12.3.2 Other developments
  • 13.1.13 ARTIVION, INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Other developments
  • 13.1.14 STRYKER CORPORATION
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 LIFETECH SCIENTIFIC CORPORATION
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
  • 13.1.16 TRANSLUMINA
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
  • 13.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered.
  • 13.1.18 ENDOLOGIX LLC.
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
  • 13.1.19 BIOSENSORS INTERNATIONAL GROUP, LTD.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product approvals
• 13.2 OTHER PLAYERS
  • 13.2.1 COOK MEDICAL
  • 13.2.2 INSITU TECHNOLOGIES INC.
  • 13.2.3 IVASCULAR
  • 13.2.4 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED
  • 13.2.5 ALVIMEDICA
  • 13.2.6 ELIXIR MEDICAL

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS